ライフサイエンスコーパス: ERbeta

1 ERbeta agonists promoted apoptosis of GBM cells, and mec

2 ERbeta also interacts with components of the cytoplasmic

3 ERbeta expression was highly variable.

4 ERbeta interfered with this recruitment by relocalizing

5 ERbeta is involved in migration of cortical neurons and

6 ERbeta overexpression further enhanced the survival of m

7 ERbeta represses ERalpha-mediated activation of the ERE

8 ERbeta-EGFP cells expressed oxytocin more abundantly in

9 ERbeta-ligand treatment in the cuprizone model further i

10 ERbeta-regulated factors are involved in cell adhesion,

11 ERbeta-specific signaling is reduced in patients with ch

12 ed in prostate cancer above Gleason grade 3, ERbeta is a potential drug target at the initial stage o

13 wed antagonistic activity for ERbeta (IC(50)(ERbeta) = 0.2-2.7 muM), but no interaction with ERalpha.

14 he apoptotic effect of 3beta-Adiol-activated ERbeta.

15 onclude that ligands specifically activating ERbeta could be useful pharmaceuticals in the treatment

16 onphosphorylatable, transcriptionally active ERbeta mutant retained antitumor activity but circumvent

17 Additionally, ERbeta overexpressing cells had a higher number of gamma

18 t in PCa, samples from men treated with ADT, ERbeta, and INPP4B expression were maintained in some sa

19 oduced by splicing between exons 2 and 4, an ERbeta protein was expressed in nuclei of prostate epith

20 inhibition of enhanced ERbeta activity by an ERbeta-selective antagonist suppressed mouse ectopic les

21 e [ERbeta(OS-/-)]), prompted us to create an ERbeta knockout mouse by deleting the ERbeta gene with t

22 In the present study, we created an ERbeta exon 3-deleted mouse (ERbeta-Deltaex3) and confir

23 pha agonist in males, whereas in females, an ERbeta agonist increased mEPSC frequency.

24 In males, an ERbeta agonist mimicked the postsynaptic effects of E2 t

25 l development and examined the effects of an ERbeta-selective ligand (LY3201) with a combination of g

26 cial effects of ERbeta1 on AKT signaling, an ERbeta agonist should be added along with ADT.

27 h doses decreased Ca(2+) currents through an ERbeta-mediated mechanism and simultaneously increased C

28 from ERbeta-Deltaex3 prostates, there was an ERbeta-dependent retardation of migration of activator p

29 ade obese by Western diet, treatment with an ERbeta selective agonist (LY3201) reduced the number of

30 nto neural lineages, we compared control and ERbeta knockout (BERKO) mESCs at defined stages of neura

31 EB treatment in the GFP (GFP + EB) and ERbeta (ERbeta + EB) groups failed to improve episodic s

32 ession of the estrogen receptors ERalpha and ERbeta and demonstrate that the window for estradiol's b

33 e, lobular cancer expresses both ERalpha and ERbeta but with very few Ki67-positive cells.

34 ulates memory independently from ERalpha and ERbeta by activating JNK signaling, rather than ERK sign

35 iproliferative and downregulated ERalpha and ERbeta expression in MCF-7 breast cancer cells.

36 ges were obtained from patients; ERalpha and ERbeta expression were verified using data from the tota

37 u transgenic mice, we found that ERalpha and ERbeta expression, mammary tumorigenesis, and survival a

38 Individual quantification of ERalpha and ERbeta expression, rather than total ER levels, might en

39 elicited an increase in mammary ERalpha and ERbeta expression.

40 ERalpha and ERbeta form heterodimers binding DNA at specific oestrog

41 PET of ERalpha and ERbeta levels could provide more insight in response to

42 Estrogen can bind to ERalpha and ERbeta localized at the plasma membrane as well as G-pro

43 ERalpha and ERbeta regulation of gene transcription is further modul

44 Estrogen receptors ERalpha and ERbeta share considerable sequence homology yet exert op

45 the classical estrogen receptors ERalpha and ERbeta were robustly expressed in the adult visual corte

46 examine the role of ER subtypes (ERalpha and ERbeta) in regulating the ethanol sensitivity of VTA neu

47 ing FOXL2, RSPO1, CYP19A1, WNT4, ERalpha and ERbeta, after one postnatal year in the ovotestis.

48 intracellular estrogen receptors ERalpha and ERbeta, little is known about the role that the membrane

49 he classical estrogen receptors, ERalpha and ERbeta, to facilitate hippocampal memory in female mice.

50 s of the estrogen receptor (ER), ERalpha and ERbeta, were determined.

51 binding to 2 nuclear receptors, ERalpha and ERbeta, which differentially regulate gene transcription

52 diated by the estrogen receptors ERalpha and ERbeta, which function as ligand-activated transcription

53 The ER consists of 2 isoforms, ERalpha and ERbeta, which have distinct biologic functions.

54 udy, we report that IQGAP1 binds ERalpha and ERbeta.

55 f the nuclear estrogen receptors ERalpha and ERbeta.

56 ed transcriptional activation of ERalpha and ERbeta.

57 s suggest that both endogenous estradiol and ERbeta activation facilitate the ability of the IL-mPFC

58 Using ERbeta-overexpression and ERbeta-KO GBM model cells, we have provided the evidence

59 ogous recombination (HR) mediated repair and ERbeta reduced expression and activation of ATM upon DNA

60 (IC50 values: 40 and 8 nM, respectively) and ERbeta (IC50 values: 19 and 15 nM).

61 s in a negative feedback loop in TGFbeta and ERbeta signaling pathways as evidenced by the potentiati

62 In 2008, another ERbeta mutant mouse was generated by deleting ERbeta exo

63 ere perform a rigorous validation of 13 anti-ERbeta antibodies, using well-characterized controls and

64 Using two different anti-ERbeta antibodies, we showed that an in-frame ligand bin

65 etermining the SUVs can be applied to assess ERbeta levels.

66 gh network prediction models have associated ERbeta with the EnR stress response, its role as regulat

67 on-neuroendocrine (presumably pre-autonomic) ERbeta-EGFP neurons predominated in the posterior PVN.

68 ogen receptor alpha (ERalpha), but not beta (ERbeta), mRNA, prevented the induction of priming by low

69 he two receptors are estrogen receptor beta (ERbeta) and liver X receptor beta (LXRbeta).

70 rs DLX5 and EGR3 and estrogen receptor beta (ERbeta) directly controlling its expression in different

71 r alpha (ERalpha) or estrogen receptor beta (ERbeta) in the hippocampus of aged animals would restore

72 Estrogen receptor beta (ERbeta) is emerging as a critical factor in understandin

73 Estrogen receptor beta (ERbeta) is essential for migration of neurons and glial

74 By contrast, estrogen receptor beta (ERbeta) is expressed in many brain regions, yet few stud

75 Estrogen receptor beta (ERbeta) is expressed in microglia, macrophages within th

76 In 1998, an estrogen receptor beta (ERbeta) knockout (KO) mouse was created by interrupting

77 out the phenotype of estrogen receptor beta (ERbeta) knockout mouse, created by removing the DNA-bind

78 is the precursor for estrogen receptor beta (ERbeta) ligands, 5AR inhibitors could potentially limit

79 While estrogen receptor beta (ERbeta) may impact the progression of non-small cell lun

80 Estrogen receptor beta (ERbeta) selective agonists are considered potential ther

81 colleagues show that estrogen receptor beta (ERbeta) signaling can act tumor-suppressive predominantl

82 ediated knockdown of estrogen receptor beta (ERbeta), but not ERalpha, abolished the effect of E2 on

83 studies suggest that estrogen receptor beta (ERbeta), may function as a tumor suppressor in GBM.

84 ects are mediated by estrogen receptor beta (ERbeta), which reduces chromatin occupancy and transcrip

85 Activation of estrogen receptor beta (ERbeta)-expressing neurons regulates the mammalian stres

86 pionitrile (DPN), an estrogen receptor beta (ERbeta)-specific agonist, and to a lesser extent 17alpha

87 lowing activation of estrogen receptor beta (ERbeta, ESR2).

88 The discovery of oestrogen receptor beta (ERbeta/ESR2) was a landmark discovery.

89 bition of microglial estrogen receptor-beta (ERbeta) function corrects the retinal abnormalities in f

90 ion was induced with estrogen receptor-beta (ERbeta) ligand treatment, and up-regulation of cholester

91 a+/+ mice, indicating a relationship between ERbeta and FOXO3a expression.

92 of natural estrogen-like compounds that bind ERbeta with high selectivity.

93 Both ERbeta and LXRbeta have potent anti-inflammatory activit

94 As both ERbeta and LXRbeta are ligand-activated transcription fa

95 the 5AR inhibitor dutasteride requires both ERbeta and TGFbeta.

96 The regulation of FOXO3a by ERbeta in normal basal epithelial cells indicates a func

97 ominantly through the regulation of genes by ERbeta in the tumor, not in the microenvironment, and po

98 In these cells, INPP4B was induced by ERbeta ligands, and this induction was accompanied by in

99 ressed, but in the high-grade lobular cancer ERbeta was lost and ERalpha and Ki67 expression were abu

100 Rbeta mutant mouse was generated by deleting ERbeta exon 3 which encodes the first zinc finger in the

101 al and 21 malignant human tissues, we detect ERbeta protein in testis, ovary, lymphoid cells, granulo

102 sent in ERbeta, but not in ERalpha, dictates ERbeta-specific activation of transcription and is requi

103 iproliferative and selectively downregulated ERbeta.

104 st), PPT (ERalpha-specific agonist) and DPN (ERbeta-specific agonist) on resistance arteries were att

105 embers and demonstrated loss of ESR2-encoded ERbeta expression in the MTC tumour.

106 Since the endogenous ERbeta ligand, 3beta-Adiol, is lost upon long-term ADT,

107 estrogen receptor (ER) beta levels, enhanced ERbeta activity was detected in endometriotic tissues, a

108 otic tissues, and the inhibition of enhanced ERbeta activity by an ERbeta-selective antagonist suppre

109 nuclear receptors, alpha and beta (ERalpha, ERbeta), is an important mechanism of transcriptional re

110 t subordinate females have elevated ERalpha, ERbeta and OTR mRNA compared to dominant females.

111 viral vectors were used to express ERalpha, ERbeta, or green fluorescent protein (GFP) in the CA1 re

112 tology and immunohistochemistry for ERalpha, ERbeta, and progesterone receptor.

113 rent cell-signaling mechanisms from ERalpha, ERbeta, or 17beta-estradiol.

114 odulation of the estrogen receptors ERalpha, ERbeta, and GPR30.

115 ERalpha/ERbeta selectivity was also evaluated, but relatively fe

116 ts of the classic estrogen receptors ERalpha/ERbeta, whereas the opposite selectivity was found in ar

117 usly inoculated in the shoulder with ERalpha/ERbeta-expressing SKOV3 human ovarian cancer cells.

118 eleost estrogenic response, with the ERalpha:ERbeta ratio being of particular importance.

119 treatment in the GFP (GFP + EB) and ERbeta (ERbeta + EB) groups failed to improve episodic spatial m

120 els of ERbeta, macrophages in CLS do express ERbeta.

121 Since GBM express ERbeta, a second receptor for estrogen, targeting ERbeta

122 roximately 80% of epithelial cells expressed ERbeta.

123 More importantly, GBM cells expressing ERbeta had increased survival when compared to control G

124 ficial chromosome transgenic mice expressing ERbeta identified by enhanced green fluorescent protein

125 Compounds showed antagonistic activity for ERbeta (IC(50)(ERbeta) = 0.2-2.7 muM), but no interactio

126 isoflavones, especially of high affinity for ERbeta.

127 or ERs, with a 3.5 times higher affinity for ERbeta.

128 s has been shown to have a high affinity for ERbeta.

129 tors (ERs) including beneficial affinity for ERbeta.

130 ivation of transcription and is required for ERbeta-dependent inhibition of cancer cell growth in cul

131 Phosphorylation of Y36 was required for ERbeta-mediated coactivator recruitment to ERbeta target

132 lobular cancer and (ii) a potential role for ERbeta agonists in preventing in situ ductal cancers fro

133 s to catecholamines reveals a novel role for ERbeta in controlling browning of adipose tissue.

134 fy a nonredundant, immunoprotective role for ERbeta-specific signaling in TGF-beta-dependent regulato

135 r imaging and shows relative selectivity for ERbeta.

136 r imaging and shows relative selectivity for ERbeta.

137 ng pharmacological tools as well as DRG from ERbeta(-/-) mice indicate that this BPA effect involves

138 Moreover, with nuclear extracts from ERbeta-Deltaex3 prostates, there was an ERbeta-dependent

139 e of estradiol (nonselective) and genistein (ERbeta-selective), respectively.

140 adiol (nonspecific ER agonist) or genistein (ERbeta-selective agonist).

141 Concurrently, COX-2 positively impacts ERbeta action through its effect on the expression of a

142 In ERbeta-/- mice, there was a significant increase in the

143 -EGFP and found developmental alterations in ERbeta expression within the cortex, hippocampus, and hy

144 etic analysis methods to quantify changes in ERbeta availability with (18)F-FHNP PET.

145 ung female mice, NR1 density is decreased in ERbeta-PVN dendrites thus reducing NMDA receptor activit

146 We also report a sex difference in ERbeta in the bed nucleus of the stria terminalis, with

147 developmental changes and sex differences in ERbeta indicate a mechanism through which estrogens migh

148 emonstrate chemoarchitectural differences in ERbeta neurons of the mouse PVN that are different from

149 enhanced green fluorescent protein (EGFP) in ERbeta-containing cells were implanted with osmotic mini

150 r-intensified immunogold (SIG) was mainly in ERbeta-EGFP dendrites.

151 tral prostate (VP) and mammary gland (MG) in ERbeta(crispr-/-) mice was similar to, but more severe t

152 ation of a tyrosine residue (Y36) present in ERbeta, but not in ERalpha, dictates ERbeta-specific act

153 nce NMDA receptor NR1 subunit trafficking in ERbeta-containing PVN neurons.

154 aged females, NR1 density is upregulated in ERbeta-PVN dendrites and ultimately leads to the neurohu

155 samples, elevated phosphorylation of Y36 in ERbeta correlated with high levels of c-ABL but low EYA2

156 eral identified NOTCH1 regulators, including ERbeta, is frequently compromised in skin, head and neck

157 Experimentally increased ERbeta expression or treatment with ERbeta agonists inhi

158 active Notch1 through a mechanism involving ERbeta to protect the endothelium in TNFalpha-induced in

159 n channel expression, in a process involving ERbeta.

160 Furthermore, a keratinocyte ERbeta-dependent program of gene expression is subverted

161 ands, 5AR inhibitors could potentially limit ERbeta activation, which maintains prostate tissue homeo

162 ith preferential binding affinity for medaka ERbeta subtypes, which are highly expressed in male meda

163 sette (Oliver Smithies ERbeta knockout mice [ERbeta(OS-/-)]), prompted us to create an ERbeta knockou

164 pressing EGFP under the control of the mouse ERbeta promoter (ERbeta-EGFP) to examine the chemical ar

165 , we created an ERbeta exon 3-deleted mouse (ERbeta-Deltaex3) and confirmed that the only observable

166 eliminated from the mouse genome and that no ERbeta mRNA or protein was detectable in tissues of this

167 invasive ductal cancers neither ERalpha nor ERbeta was expressed, but in the high-grade lobular canc

168 vity of ER (estrogen receptor)-alpha but not ERbeta through the modulation of ERalpha phosphorylation

169 role for inflammatory cell ERalpha, but not ERbeta, in poor healing associated with an altered cytok

170 l estrogen receptor alpha (ERalpha), but not ERbeta, in the liver plays a critical role in the format

171 g immunohistochemistry, we found that 90% of ERbeta-immunoreactivity (-ir) colocalized with EGFP.

172 Impaired Treg suppression in the absence of ERbeta was associated with aberrant overexpression of Ts

173 of COX-2 on the tissue-protective action of ERbeta.

174 Importantly, activation of ERbeta inhibited angiogenesis and lymphangiogenesis, pos

175 In Granta-519 MCL tumors, activation of ERbeta reduced expression of BAFF and GRB7, 2 important

176 not clear whether the antitumor activity of ERbeta can be mobilized in breast cancer cells.

177 clusion:(18)F-FHNP PET enables assessment of ERbeta availability in tumor-bearing rats.

178 )pyridin-3-ol ((18)F-FHNP) for assessment of ERbeta levels with PET.

179 direct effect, ChIP assays showed binding of ERbeta to the putative estrogen-response element of a ke

180 -Chloro IndCl analogues represent a class of ERbeta ligands that offer significant remyelination and

181 ompare expression levels and distribution of ERbeta in the male and female mouse forebrain on the day

182 tive analysis, we mapped the distribution of ERbeta-EGFP and found developmental alterations in ERbet

183 previous work suggests that dysregulation of ERbeta-specific signaling contributes to enhanced intest

184 show that the growth-suppressing effects of ERbeta agonist are also valid for human B-cell lymphomas

185 Here, we tested the effects of ERbeta targeting on LHON mitochondrial defective metabol

186 However, the effects of ERbeta-specific ligands on human or murine pathogenic im

187 T cells only, indicating that expression of ERbeta by these cells is crucial for the observed therap

188 Expression of ERbeta failed to improve cognition and was associated wi

189 was associated with increased expression of ERbeta in the nuclei of neurons in the sympathetic gangl

190 in males there was very little expression of ERbeta in the SAT and very little expression of the beta

191 intestine, whereby homeostatic expression of ERbeta normally functions to limit Treg-specific express

192 In addition, the expression of ERbeta, FOXO3a and PUMA is comparable and higher in beni

193 mice engineered to lack global expression of ERbeta, we observed dramatic, female-specific exacerbati

194 sal epithelial cells indicates a function of ERbeta in cell differentiation and maintenance of cells

195 e present study investigates the function of ERbeta in macrophages within CLS.

196 uestions about the physiological function of ERbeta.

197 Furthermore, this gain of ERbeta function enhances epithelial-mesenchymal transiti

198 Notably, gain of ERbeta function stimulated the progression of endometrio

199 p into sustained ectopic lesions via gain of ERbeta function.

200 Growth of ERbeta-positive breast cancer and melanoma cells was sig

201 e humans, rodents express a novel isoform of ERbeta (mERbeta2) with a modified ligand-binding domain

202 Conditional KOs of ERbeta in OLCs demonstrated that increased cholesterol-s

203 which display unprecedentedly high levels of ERbeta selectivity for this class of compounds, both in

204 es in the blood have no detectable levels of ERbeta, macrophages in CLS do express ERbeta.

205 We conclude that very little of ERbeta transcriptional activity depends on binding to cl

206 r higher, where there is substantial loss of ERbeta, FOXO3a and PUMA.

207 Moreover, the ventral prostate of ERbeta-/- mice had decreased expression of FOXO3a and PU

208 l probe for helping to elucidate the role of ERbeta in cancer cells.

209 We examined the role of ERbeta in the DNA damage response of GBM cells, and test

210 ts had worse survival outcomes than those of ERbeta-negative NSCLC female patients.

211 In the VP of 6-mo-old ERbeta(crispr-/-) mice there was epithelial hyperplasia,

212 2 had a compound-specific negative effect on ERbeta/ligand-mediated activity and ER target genes when

213 ort hairpin RNAs targeting either ERalpha or ERbeta into the VTA and found that knockdown of each rec

214 Knockdown of FOXO3a or ERbeta expression abolished the increase of PUMA in resp

215 ogen receptor (ER) agonists (ERalpha /PPT or ERbeta: DPN); or non-selective sex hormone receptor anta

216 is a highly proliferative, ERalpha-positive, ERbeta-negative disease, lobular cancer expresses both E

217 the synthesis and evaluation of a potential ERbeta-selective PET tracer: 2-(18)F-fluoro-6-(6-hydroxy

218 er the control of the mouse ERbeta promoter (ERbeta-EGFP) to examine the chemical architecture of PVN

219 to examine the chemical architecture of PVN ERbeta cells.

220 ytochemistry, but careful exploration of PVN ERbeta neurons in mice has been hindered by a lack of sp

221 of fluorogold revealed that the rostral PVN ERbeta-EGFP cells are neuroendocrine neurons whereas non

222 rmacokinetic models were applied to quantify ERbeta availability in the tumor.

223 The most suitable parameter to quantify ERbeta expression is the Ki However, a simplified static

224 that Ki is a suitable parameter to quantify ERbeta expression.

225 -cells from wild-type and oestrogen receptor ERbeta-/- mice, we found that exposure to increasing dos

226 effect on binge-like drinking than reducing ERbeta, consistent with the ability of ERalpha to alter

227 dentify a signaling circuitry that regulates ERbeta-specific antitumor activity and has potential as

228 A 3-day-treatment with a selective ERbeta agonist, LY3201, induced browning of SAT in 1-yea

229 active Notch1 was abrogated after silencing ERbeta.

230 the gene with a neocassette (Oliver Smithies ERbeta knockout mice [ERbeta(OS-/-)]), prompted us to cr

231 mice has been hindered by a lack of specific ERbeta antisera.

232 the presence of phosphorylated Y36-specific ERbeta was strongly associated with both disease-free an

233 phosphorylation status of Y36 and subsequent ERbeta function.

234 enous immune surveillance for cell survival, ERbeta interacts with cellular apoptotic machinery in th

235 ulates cell proliferation and cell survival, ERbeta promotes apoptosis.

236 Importantly, synthetic ERbeta-specific ligands acting directly on CD4(+) T cell

237 herapeutic effect of the selective synthetic ERbeta agonist LY500307 using in vitro and in vivo GBM m

238 In this article, we show that the synthetic ERbeta-specific ligand 4-(2-phenyl-5,7-bis[trifluorometh

239 urvival assays using multiple epitope tagged ERbeta expressing established and primary GBM cells demo

240 a, a second receptor for estrogen, targeting ERbeta with a selective agonist may be a potential novel

241 These results suggest that targeting ERbeta with agonists may be valuable in the treatment of

242 Thus, targeting ERbeta may become a therapeutic strategy for LHON specif

243 sed monoclonal PPZ0506, specifically targets ERbeta in immunohistochemistry.

244 We conclude that ERbeta expression is induced in macrophages in CLS withi

245 We conclude that ERbeta is a tumor suppressor gene in the VP and MG where

246 lts from the above studies demonstrated that ERbeta can promote NSCLC VM formation and cell invasion

247 shed and primary GBM cells demonstrated that ERbeta sensitizes GBM cells to DNA damaging agents inclu

248 2 or DPN, providing functional evidence that ERbeta interacts with metabotropic glutamate receptor 1a

249 el cells, we have provided the evidence that ERbeta is required for optimal chemotherapy induced DNA

250 Results support emerging evidence that ERbeta subtypes are critically involved in the teleost e

251 n human prostate cancer cells, we found that ERbeta causes apoptosis by increasing the expression of

252 We found that ERbeta was induced in embryoid bodies (EBs) and neural p

253 istry data from NSCLC tissues and found that ERbeta-positive NSCLC female patients had worse survival

254 We also show by immunohistochemistry that ERbeta is expressed in primary MCL tissue.

255 multiple NSCLC cell lines also revealed that ERbeta could increase the VM formation and cell invasion

256 Additionally, IHC analysis revealed that ERbeta tumors had increased expression of gammaH2AX and

257 ng disseminating Raji BL cells, we show that ERbeta activation reduces dissemination of grafted Raji

258 In the present study we show that ERbeta influences browning of subcutaneous adipose tissu

259 Together these results show that ERbeta plays a key role in sexual behavior regulation an

260 We also showed that ERbeta localize to the mitochondria of RGCs.

261 Mechanistic studies showed that ERbeta plays an important role in homologous recombinati

262 Our data suggest that ERbeta is an important component for differentiation int

263 olecular mechanism dissection suggested that ERbeta could increase the lncRNA-MALAT1 (MALAT1) express

264 et enrichment analysis (GSEA) suggested that ERbeta-modulated genes were correlated negatively with h

265 formation and cell invasion via altering the ERbeta/MALAT1/miR145-5p/NEDD9 signaling.

266 ate an ERbeta knockout mouse by deleting the ERbeta gene with the use of CRISPR/Cas9 technology.

267 hydrocarbon receptor activation enhanced the ERbeta ligand-mediated expansion of IL-10-producing T ce

268 of a number of steroidogenic enzymes in the ERbeta ligand metabolic pathway.

269 imilar to, but more severe than, that in the ERbeta(OS-/-)mice.

270 n prostate epithelium was not altered in the ERbeta-Deltaex3 mouse.

271 ng domain and C terminus were present in the ERbeta-Deltaex3 protein.

272 ed by removing the DNA-binding domain of the ERbeta gene or interruption of the gene with a neocasset

273 We confirmed that the ERbeta gene was eliminated from the mouse genome and tha

274 ression of FOXO3a and PUMA compared with the ERbeta+/+ mice, indicating a relationship between ERbeta

275 tment of PC3, 22Rv1 and LNCaP cells with the ERbeta-specific ligands 3beta-Adiol (5alpha-androstane-3

276 In addition, these ERbeta-specific ligands promoted the induction and maint

277 Finally, these ERbeta-selective agonists were found to inhibit prolifer

278 Thus ERbeta agonists may be used to alleviate CLS-related bre

279 Thus, ERbeta-specific ligands targeting pathogenic Th17 cells

280 r ERbeta-mediated coactivator recruitment to ERbeta target promoters.

281 vels of FOXO3a were increased in response to ERbeta expression or treatment of PC3, 22Rv1 and LNCaP c

282 Furthermore, compared with total ERbeta, the presence of phosphorylated Y36-specific ERbe

283 Here, upregulation of wild-type ERbeta (ERbeta1) or treatment with ERbeta agonists enhan

284 Using ERbeta-overexpression and ERbeta-KO GBM model cells, we

285 By using ERbeta-deficient mice, we now demonstrate that this inhi

286 RNA-seq studies using ERbeta overexpression models revealed downregulation of

287 To examine whether ERbeta influences differentiation of mouse embryonic ste

288 ge response of GBM cells, and tested whether ERbeta sensitizes GBM cells to chemotherapy.

289 However, the mechanism(s) by which ERbeta contributes to GBM suppression and chemotherapy r

290 eus of P21, but not P0 or P4, mice, in which ERbeta-EGFP-immunoreactive cells were densely clustered

291 olII) recruitment to the NOTCH1 locus, while ERbeta controls NOTCH1 transcription through RNA PolII p

292 also correlated (r(2) = 0.47; P = 0.04) with ERbeta expression.

293 0.46, P = 0.03) and was not associated with ERbeta expression (rho = 0.21, P = 0.33).

294 These effects were abolished in cells with ERbeta knockdown by silencing receptor expression or by

295 use, we found a moderate colocalization with ERbeta-ir (48 +/- 16%) in the middle PVN.

296 estrogen receptor alpha-ir colocalized with ERbeta-EGFP at low levels (15 +/- 3%).

297 litis amelioration was canceled in mice with ERbeta-deficient CD4(+) T cells only, indicating that ex

298 wild-type ERbeta (ERbeta1) or treatment with ERbeta agonists enhanced apoptosis in breast cancer cell

299 ncreased ERbeta expression or treatment with ERbeta agonists inhibited proliferation of SCC cells and

300 The Ki values correlated well with ERbeta expression but not with ERalpha, confirming that